Biotechnology Research · MA
TPD is a powerful drug modality that harnesses the cell’s existing protein disposal and recycling machinery to eradicate disease-causing proteins that cannot be addressed, or are poorly addressed, by other technologies, delivering a potentially transformative new way to fight disease and dramatically improve patients’ lives. Small molecule oral degraders have the opportunity to transform Immunology – they offer a potentially superior profile to injectable biologics and traditional small molecule inhibitors. Biologics can have limitations, making orals preferred by most patients. Traditional small molecule inhibitors insufficiently block pathways, which can limit efficacy. At Kymera, our shared values — Pioneer, Collaborate, and Belong — are more than just words; they’re the foundation of who we are. These principles, along with our deep commitment to improving patients’ lives, guide everything we do and unite our diverse, experienced teams around a common mission. We’re proud to be recognized as one of Boston’s top workplaces year after year, which is a reflection of our dedication to scientific excellence, authentic camaraderie, and relentless pursuit of impact. We welcome like-minded pioneers to join us on our extraordinary journey to revolutionize immunology for millions of patients around the world.